Blautia Strain A Bacterial Composition for Immune Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases, inflammatory diseases, and allergies lack effective solutions, particularly in modulating the immune response and addressing chronic conditions such as autoimmune myocarditis, diabetes mellitus type 1, and inflammatory bowel disease.

Innovation Solution

Administration of a bacterial composition comprising Blautia Strain A, including live, killed, or attenuated bacteria, and extracellular vesicles, which can be administered orally, intravenously, or subcutaneously, to modulate the immune response and treat various immune disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for autoimmune diseases and inflammatory conditions are used, then existing therapeutic options are available, but effective modulation of immune response is lacking

Engineering Contradiction:

Improveeffectiveness of immune response modulationVSAvoidability to address chronic immune disorders

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses Blautia Strain A bacteria as an intermediary mediator to modulate the immune system. The bacteria and their extracellular vesicles act as biological mediators that interact with the immune system to induce regulatory T cell responses and anti-inflammatory effects, resolving the contradiction by providing a reliable immune modulation mechanism that current treatments lack

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the parameter of immune response by introducing a specific bacterial strain that alters immune system behavior. By administering Blautia Strain A, the patent transforms the immune system's state from pathological (autoimmune/inflammatory) to regulated (tolerant/anti-inflammatory), thereby improving reliability of immune modulation while maintaining adaptability to various chronic immune disorders

Inventive Principle:

Principle #35Parameter changes

2Reliability

If traditional immune disorder treatments are administered, then standard therapy protocols are followed, but suppression of pathological immune responses is insufficient

Engineering Contradiction:

Improvesuppression of immune responseVSAvoidcomplexity of treatment composition

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the therapeutic components from the whole bacterial system by isolating and utilizing extracellular vesicles (EVs) from Blautia Strain A. These EVs contain the immunomodulatory factors needed for suppressing pathological immune responses without requiring the complete bacterial organism, thereby achieving reliable immune suppression while simplifying the treatment composition

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs a specific bacterial strain (Blautia Strain A) that can be cultured and administered as a transient therapeutic agent. The bacteria and their EVs provide the necessary immune modulation effect during their presence in the system, after which they are naturally eliminated, offering a reliable yet temporally limited treatment approach that avoids long-term complexity

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If Blautia Strain A bacterial composition is administered, then immune response modulation is achieved, but requirement for specific bacterial strain and preparation methods increases

Engineering Contradiction:

Improveinduction of anti-inflammatory responseVSAvoidproduction of bacterial composition

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent requires preliminary identification and characterization of the specific Blautia Strain A strain with the desired immunomodulatory properties. This preliminary action ensures that only bacteria meeting specific criteria are used for therapy, guaranteeing reliable induction of anti-inflammatory responses while establishing standardized protocols for strain selection and preparation

Inventive Principle:

Principle #10Preliminary action

4Adaptability or versatility

If multiple administration routes are available for Blautia Strain A, then flexibility in treatment is improved, but determination of optimal dosing and route selection becomes more complex

Engineering Contradiction:

Improveadministration route optionsVSAvoidselection of administration method

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The patent demonstrates that Blautia Strain A and its extracellular vesicles can be administered through multiple routes (oral, intravenous, subcutaneous), making the treatment universally applicable across different patient needs and disease presentations. This multi-functionality in administration routes enhances adaptability while the underlying mechanism remains consistent, simplifying the decision-making process for clinicians

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS10493113B2Compositions and methods for treating disease using a <i>Blautia </i>strain

Publication Date: 2019.12.03 EVELO BIOSCIENCES INC

AI summary

Provided herein are methods and compositions related to Blautia Strain A useful as therapeutic agents.